Fusion Pharmaceuticals Q1 2024 GAAP EPS $(0.40) Misses $(0.37) Estimate
Fusion Pharmaceuticals Q1 2024 GAAP EPS $(0.40) Misses $(0.37) Estimate
Fusion Pharmaceuticals 2024年第一季度GAAP每股收益美元（0.40）未达到预期（0.37 美元）
Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 11.11 percent increase over losses of $(0.45) per share from the same period last year.
Fusion Pharmicals（纳斯达克股票代码：FUSN）公布的季度亏损为每股0.40美元，比分析师普遍预期的0.37美元（0.37美元）低8.11％。这比去年同期每股亏损0.45美元（0.45美元）增长了11.11％。